Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume 236, Issue 4, Pages 2430-2442Publisher
WILEY
DOI: 10.1002/jcp.30041
Keywords
ACE2; angiotensin-converting enzyme 2; ARDS; COVID-19; miRNA; SARS-CoV-2
Categories
Ask authors/readers for more resources
COVID-19, caused by the novel coronavirus, has posed a global challenge and highlights the urgent need for an effective vaccine. Understanding the virus's structure, entry mechanism, and pathogenesis is crucial in developing treatment strategies.
COVID-19, a new disease caused by the 2019-novel coronavirus (SARS-CoV-2), has swept the world and challenged its culture, economy, and health infrastructure. Forced emergence to find an effective vaccine to immunize people has led scientists to design and examine vaccine candidates all over the world. Until a vaccine is developed, however, effective treatment is needed to combat this virus, which is resistant to all conventional antiviral drugs. Accordingly, more about the structure, entry mechanism, and pathogenesis of COVID-19 is required. Angiotensin-converting enzyme 2 (ACE2) is the gateway to SARS-CoV and SARS-CoV-2, so our knowledge of SARS-CoV-2 can help us to complete its mechanism of interaction with ACE2 and virus endocytosis, which can be interrupted by neutralizing small molecules or proteins. ACE2 also plays a crucial role in lung injury.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available